Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2636
    +0.0014 (+0.11%)
     
  • USD/JPY

    151.2210
    -0.1510 (-0.10%)
     
  • Bitcoin USD

    69,466.82
    -1,921.98 (-2.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Pfizer lung cancer drug beats chemo for previously untreated patients

March 25 (Reuters) - Pfizer Inc's Xalkori delayed progression of lung cancer longer than chemotherapy in patients who had never previously been treated for the disease, according to results of a late-stage study released on Tuesday.

The medicine, which received U.S. approval in 2011 for lung cancer patients who have a specific gene mutation, had shown in a previous Phase III trial that it significantly delayed disease progression among those who have already undergone chemotherapy for non-small-cell lung cancer, the most common form of the illness.

The drug is used among patients who have a mutation in the so-called ALK gene, as determined by an approved diagnostic test. The mutation only occurs in a small percentage of patients with lung cancer, but makes them good candidates for treatment with Xalkori.

Xalkori, whose chemical name is crizotinib, had global sales of $89 million in the fourth quarter. Pfizer is also developing an array of other cancer medicines that work through new mechanisms, with the aim of becoming a major player in the oncology field.

Pfizer shares were up 0.6 percent at $31.68 in morning trading on the New York Stock Exchange.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)

Advertisement